Antitumor effect of vaccinia virus in glioma model

Oncology Research

Volumn 11, Issue 3, 1999, Pages 133-144

  Timiryasova, Tatyana M ^a   Li, Jun ^a   Chen, Bing ^a   Chong, Daneil ^a   Langridge, William H R ^a   Gridley, Daila S ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

Gene expression; Glioma; P53; Tumor; Vaccinia virus

Indexed keywords

ANTINEOPLASTIC AGENT; LIVE VACCINE; PROTEIN P53; RECOMBINANT PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL; APOPTOSIS; ARTICLE; BRAIN TUMOR; CELL DIVISION; GENETICS; GLIOMA; HUMAN; IMMUNOLOGY; METABOLISM; MORTALITY; MOUSE; NUDE MOUSE; PATHOGENICITY; PATHOLOGY; RAT; SURVIVAL RATE; TISSUE DISTRIBUTION; VACCINIA VIRUS; VIROLOGY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; GLIOMA; HUMANS; MICE; MICE, NUDE; RATS; RECOMBINANT PROTEINS; SURVIVAL RATE; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0032620547     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Kenncy, S.; Pagano, J. S. Viruses as oncolytic agents: A new age for "therapeutic" viruses? J. Nail. Cancer Inst. 86:1185-1186; 1994.
2. Asada, T. Treatment of human cancer \vith mumps virus. Cancer 34:1907-1928: 1974.
3. Gross, S. Measles and leukaemia. Lancet 1:397-398; 1971.
4. Csatary, L. K. Viruses in the treatment of cancer. Lancet 2:825; 1971.
5. Martuza. R. L.; Malick, A.; Marken, J. M.: Rufncr, K. I.; Coen, D. M. Expérimental therapy of human glioma by means of genetically engineered virus mutant. Science 252:854-856; 1991.
6. Mineta, T.; Rahkin, S. D.; Yazaki, T.; Hunter, W. D.; Martuza, R. L. Attenuated multi-mutated herpes simplex vims-1 for the treatment of malignant gliomas. Nat. Med. 1:928-943; 1995.
7. Bischoff, J. R.; Kirn, D. H.: Williams. A.; Heise, C.; Horn, S.; Muna. M.; Ng, L.; Nue. J. A.; Sampson-Johannes, A.; Fallacy, A.; McCormick. F. An adenovirus mutant that replicates selectively in p53-deficicnt human tumor cells. Science 274:373-376; 1996.
8. Fridman, T. The promise and ovcrpromise of human gene therapy. Gene Ther. 1:217-218; 1994.
9. Mastrangelo, M. J.; Berd. D.; Nathan. F. F..: Lattime, E. Gene therapy for human cancer: An assay for clinicians. Semin. Oncol. 23:4-21; 1996.
10. Morgan, R. A.; Andcrson. \V. F. Human gene therapy. Annu. Rev. Biochcm. 62:191-217; 1993.
11. Ali, M.: Lemoine, N. R.; Ring. C. J. A. The use of DNA viruses as vectors for gene therapy. Gene Thcr. 1:367-384; 1994.
12. Miller, N.; Ville, R. Targeted vector for gene therapy. FASEB J. 9:190-199; 1995;
13. Kramm, C. M.; Scna-Esteves, M.; Barnctt. F. H.; Rainov, N. G.; Schuhack. D. E.; Yu, J. S.; Pechan, P. A.: Paulus, W.; Chiocca, E. A: Brcakcfield. X. O. Gene therapy for brain tumors. Brain Pathol. 5:345-381; 1995.
14. Gallardo. D.; Drazan. K. E.; McBride, W. II. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensilivity. Cancer Res. 56:4891-4893; 1996.
15. Qin, H.: Chatterjec. S. K. Cancer gene therapy using tumor cells infected with recombinam vaccinia virus expressing GM-CSF. Hum. Gene Ther. 7:1853-1860; 1996.
16. Yu, J. S.; Burwick, J. A.; Dranoff, G.; Breakefield, X. O. Gene therapy for metastatic brain tumors by vaccination with granulocytc-macrophage colony-stimulatin factor-transduced tumor cells. Hum. Ge"ne Ther. 8:1065-1072'; 1997.
17. Moss, B. Genetically engineered poxvirus for recombinant gene expression, vaccination and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348: 1996.
18. Moss. B. Vaccinia virus: A tool for research and development. Science 252:1660-1667; 1991.
19. Fodor, I. Live recombinant vaccines for humans. Acta Biotechnol. Acad. Verlag 11:215-221;'1991.
20. Bronte, V.; Carrol, M. W.; Goletz, T. J.; Wang, M.; Ovcrwijk, W. W.; Marincola, F.; Rosenbcrg, S. A.; Moss. B.; Restifo, N. P. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA 94:3183-3188; 1997.
21. Meko, J. B.; Yim. J. H.; Tsung, K.; Norton, J. A. High cytokine production and effective antitumor activity of a rccombinant vaccinia virus encoding murine interleukin 12. Cancer Res. 55:4765-4770; 1995.
22. Uzcndoski, K.; Kantor, J. A.; Abrams, S. I.; Schlom, J.; Hodge, J. W. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: Induction and potentiation of antitumor responses. Hum. Gene Ther. 8: 851-860: 1997.
23. Gridley, D. S.; Andres, M. L.; Li, J.; Timiryasova, T.; Chen, B.; Fodor, I. Evaluation of radiation effect against C6 glioma in combination with vaccinia \irus-p53 gene therapy. Int. J. Oncol. 13: 1093-1098; 1998.
24. Winco, P. A.; Tony, T.; Bolden, B. A. Cancer statistics. CA Cancer J. Clin. 45:8-30; 1995.
25. Salcman, M.; Kaplan, R. Intracranial tumors in adults. In: Moosa, A. R.; Schimpff, S. C.; Robson, M. C., eds. Comprehensive textbook of oncology. Baltimore; 1991:1339-1352.
26. Bartek, J.; Barkova, }.; Vojtesek, S.; Staskova, Z.; Lukas, J.; Rejthar, A.; Kovarik, J.; Midgley, C. A.; Gannon, J. V.; Lane, D. P. Abberant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703; 1991.
27. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. p53 mutations in human cancers. Science 253:49-53; 1991.
28. Donehower, L. A. Effects of p53 mutation on tumor progression: Recent insights from mouse tumor models. Bioch. Biophys. Acta 1242:171-176; 1996.
29. Asai, A.; Miyagi, Y.; Sugiyama, A.; Gamanuma, M.; Hong, S. H.; Takamoto, S.; Nomura, K.; Matsutani, M.; Takakura, K.; Kuchino, Y. Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J. Neurooncol. 19:259-268; 1994.
30. Timiryasova, T. M.; Kopylova-Sviridova, T. N.; Fodor, I. Expression of the reporter genes in the different regions of vaccinia virus genome. Mol. Biol. 27:392-401; 1993.
31. Baker, S. J.; Markowitz, S.; Fearon, E. R.; Willson, J. K. V.; Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915; 1990.
32. Goebcl, S. J.; Johnson, G. P.; Perkus, M.E.; Davis, S. W.; Winslow, J. P.; Paoletti, E. The complete DNA sequence of vaccinia virus. Virology 179:247-266; 1990.
33. Langridge, W. H. R.; Krausova, V. I.; Szalay, A. A.; Fodor, I. Detection of baculovirus gene expression in insect cells and larvae by low light video image analysis. J. Virol. Methods 61:151-156; 1996.
34. Chakrabarti, S.; Brechung, K.; Moss, B. Vaccinia virus expression vector: Coexpression of -galactosidase provides visual screening of recombinant vims plaques. Mol. Cell Biol. 5:3403-3409; 1985.
35. Buller, R. M. L.; Smith, G. L.; Cremer, K.; Notkins, A. L.; Moss, B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317:813-815; 1985.
36. Elkins, K. L.; Ennist, D. L.; Winegar, R. K.; Weir, J. P. In vivo delivery of interleukin-4 by recombinant vaccinia virus prevents tumor development in mice. Hum. Gene Ther. 5:809-820; 1994.
37. Li, J.; Andres, M. L.; Fodor, I.; Nelson, G. A.; Gridley, D. S. Evaluation of pGL1-TNF-α therapy in combination with radiation. Oncol. Res. 10:379-387; 1999.
38. Timiryasova, T. M.; Chen, B.; Haghighat, P.; Fodor, I. Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Int. J. Oncol. 14:845-854; 1999.
39. Gridley, D. S.; Archambcau, J. O.; Andres, M. A.; Mao, X. W.; Slater, J. M. Tumor necrosis factor-a enchances the antitumor effects of radiation against glioma xenografts. Oncol. Res. 9:217-227; 1997.
40. Ronen, D.; Teitz, Y.; Goldfinger, N.; Rotter, V. Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses. Nucleic Acids Res. 20:3435-3441; 1992.
41. Wills, K. N.; Maneval, D. C.; Menzel, P.; Harris, M. P.; Sutjipto, S.; Vaillancourt, M.-T.; Huang, W.-M.; Johnson, D. E.; Anderson, S. C.; Wen, S. F.; Bookstein, R.; Shepard, H. M.; Gregor)', R. Y. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther. 5:1079-1088; 1994.
42. Polyak, K.; Waldman, T.; He, T. C.; Kinzler, K. W.; Vogelstein, B. Genetic determination of p53-induced apoptosis and growth arrest. Genes Dev. 10:1945-1952; 1996.
43. Li, H.; Lochmuller, H.; Yong, V. W.; Karpati, G.; Nalbantoglu, J. Adenovims-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J. Neuropathol. Exp. Neurol. 56:872-878: 1997.
44. Ramsey-Ewing, A.; Moss, B. Apoptosis induced by a postbinding step of vaccinia virus entry into Chinese hamster ovary cells. Virology 242:138-149; 1998.
45. Conry, R. M.; Saleh, M. N.; Schlom, J.; Lobuglio, A. F. Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus vaccine in man. Proc. Am. Assoc. Cancer Res. 36:492; 1995.
46. Tsang, K. Y.; Kantor, J.; Abrams, S.; Panicalli, D.; Hamilton, J.; Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87: 982-990; 1995.
47. Ramshaw, I. A.; Andrew, M. E.; Philips, S. M.; Boyle, D. B.; Coupar, B. E. H. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329:545-546; 1987.
48. Whitman, E. D.; Tsung, K.; Paxson, J.; Norton, J. A. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery 116:183-188; 1994.
49. Peplinski, G. R.; Tsung. K.; Casey, M. J.; Meko, J. B.; Frcdrickson, T. N.; Buller, R. M. L.; Norton, J. A. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-lbeta. Cancer J. 2:21-27; 1996.
50. Puhlmann. M.; Gnant, M.; Brown, C. K.; Alexander, H. R.; Bartlett, D. L. Thymidine kinase-deleted vacinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum. Gene Then 10:649-657; 1999.
51. Bischoff, J. R.; Kirn, D. II.; Williams, A.; Heisc, C.; Horn, S.; Muna, M.; Ng, L.; Nye, J. A.; Sampson-Johannes, A.; Fattaey, A.; McComick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376; 1996.
52. Rothmann, T.; Hengstermann, A.; Whitaker, N. J.; Scheffner, M.; zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:9470-9478; 1998.
53. Hall, A. R.; Dix, B. R.; O'Carroll, S. J.: Braithwaite, A. W. p53dependent dependent death/apoptosis is required for a productive adenovirus infection. Nat. Mcd. 4:1068-1072; 1998.
54. Goodrum. F. D.; Ornelles, D. A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72:9479-9490; 1998.
55. Kirn, D.; Hermiston, T.; McCormick, F. ONYX-015: Clinical data are encouraging. Nat. Med. 4:1341-1342; 1998.
56. Hay, J. G.; Shapiro, N.; Sauthoff, H.; Heitner, S.; Phupakdi, W.; Rom, W. N. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral Elb-55kD gene. Hum. Gene Ther. 10:579-590;1999.
57. Rooney, J. F.; Wohlenberg, C.; Crerher, K. H.; Moss, B.; Nolkins, A. L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and effect of revaccination. J. Virol. 62:1530-1534; 1988.
58. Zhang, H.-G.; Liu, D.; Heike, Y.; Yang, P.; Wang, Z.; Wang, X.; Curiel, D. T.; Zhou, T.; Mountz, J. D. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat. Biotechnol. 16:1045-1049; 1998.
59. Toda, M.; Rabkin, S. D.; Kojima, H.; Martuza, R. L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity. Hum. Gene Ther. 10:385-393; 1999.